Mizuho Downgrades BD to Neutral | GenomeWeb

NEW YORK (GenomeWeb News) – Mizuho Securities analyst Peter Lawson today downgraded the stock of Becton Dickinson from Buy to Neutral.

Lawson noted that BD's shares, which closed at $83.94 on the New York Stock Exchange Monday, are within 4 percent of Mizuho's $87 price target. He noted that the firm's stock has risen 9 percent over the past three months and 12 percent over the past six months and no longer trades at a discount to its historical Price-t0-earnings multiple.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.